Basic Search  |  Summaries  |  Advanced Search

Violation Tracker Individual Record

Company: DuPont Pharmaceuticals Company
Current Parent Company: Bristol-Myers Squibb
Penalty: $44,500,000
Year: 2002
Date: January 15, 2002
Offense Group: competition-related offenses
Primary Offense: price-fixing or anti-competitive practices
Secondary Offense: generic drug pay for delay
Mega-Scandal: Generic Drug Pay for Delay
Violation Description: DuPont Pharmaceuticals agreed to pay over $44 million to settle litigation alleging it disseminated false and misleading information about a generic alternative to its blood thinner Coumadin.
Level of Government: federal
Action Type: private litigation
Court: District of Delaware
Civil or Criminal Case: civil
Case ID: 1:98md1232
Case Name: In re Warfarin Sodium Antitrust Litigation
Private Lawsuit Resolution Type: settlement
HQ Country of Current Parent: USA
HQ State of Current Parent: New York
Ownership Structure of Current Parent: publicly traded
Major Industry of Current Parent: pharmaceuticals
Specific Industry of Current Parent: pharmaceuticals
Source of Data: In re Warfarin Sodium Antitrust Litig., 391 F.3d 516
Link to PACER Case Docket (must be logged in): (click here)
Source Notes: If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.
Current parent company note: Parent-subsidiary relationship is current as of the most recent revision listed in the Update Log.